ArticlePeerJ2018
Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators.
Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- DPP-4 Inhibitors in Female Cancers: Opportunities for Drug Repurposing.Current issues in molecular biology · 2026Review
- Thiazolidinedione derivatives: emerging role in cancer therapy.Molecular diversity · 2025Review
- Examination of Triazolinedione-Derived Dihydropyrrole Hybrid Compounds: ER Stress-Related Apoptosis in Breast Cancer Cells, Molecular Docking, and ADMET Analysis.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.Molecular biomedicine · 2024Review
- Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.Cancers · 2024Review
- Does NUCB2/Nesfatin-1 Influence Eating Behaviors in Obese Patients with Binge Eating Disorder? Toward a Neurobiological Pathway.Nutrients · 2023Article
- Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.Frontiers in endocrinology · 2023Article
- Peptide Helix-YPPAR research · 2023Article
- A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis.International journal of environmental research and public health · 2022Article
- Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The anticancer effects of Metformin in the male germ tumor SEM-1 cell line are mediated by HMGA1.Frontiers in endocrinology · 2022Article
- Insulin Resistance and Cancer: In Search for a Causal Link.International journal of molecular sciences · 2021Review
- Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.Cancer cell international · 2021Review
- Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-PPAR research · 2021Article
- Bioactive pyrrole-based compounds with target selectivity.European journal of medicinal chemistry · 2020Review
- Obesity-related hypoxia via miR-128 decreases insulin-receptor expression in human and mouse adipose tissue promoting systemic insulin resistance.EBioMedicine · 2020Article
- Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors.Molecules (Basel, Switzerland) · 2020Article
- Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases.Nutrients · 2020Review
- MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy.Frontiers in endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThiazolidinediones (TZDs), also called glitazones, are five-membered carbon ring molecules commonly used for the management of insulin resistance and type 2 diabetes. Recently, many prospective studies have also documented the impact of these compounds as anti-proliferative agents, though several negative side effects such as hepatotoxicity, water retention and cardiac issues have been reported. In this work, we synthesized twenty-six new TZD analogues where the thiazolidinone moiety is directly connected to an N-heterocyclic ring in order to lower their toxic effects.
methodsBy adopting a widely applicable synthetic method, twenty-six TZD derivatives were synthesized and tested for their antiproliferative activity in MTT and Wound healing assays with PC3 (prostate cancer) and MCF-7 (breast cancer) cells.
resultsThree compounds, out of twenty-six, significantly decreased cellular viability and migration, and these effects were even more pronounced when compared with rosiglitazone, a well-known member of the TZD class of antidiabetic agents. As revealed by Western blot analysis, part of this antiproliferative effect was supported by apoptosis studies evaluating BCL-xL and C-PARP protein expression.
conclusionOur data highlight the promising potential of these TZD derivatives as anti-proliferative agents for the treatment of prostate and breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.